MicroRNAs and type 2 diabetes mellitus: Molecular mechanisms and the effect of antidiabetic drug treatment

Metabolism: Clinical and Experimental

Volumn 87, Issue , 2018, Pages 48-55

  Yaribeygi, Habib ^a   Katsiki, Niki ^b   Behnam, Behzad ^c,d   Iranpanah, Helia ^a   Sahebkar, Amirhossein ^e,f  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Beta cell; Insulin resistance; Micro RNAs; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; MICRORNA;

DRUG MECHANISM; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENETICS; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC NETWORKS AND PATHWAYS; MICRORNAS;

EID: 85049728147     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2018.07.001     Document Type: Review

References (115)

1. Senapati, S., Bharti, N., Bhattacharya, A., Modern lifestyle diseases: chronic diseases, awareness and prevention. Int J Curr Res Acad Rev 3 (2015), 215–223.
2. Yaribeygi, H., Farrokhi, F.R., Rezaee, R., Sahebkar, A., Oxidative stress induces renal failure: a review of possible molecular pathways. J Cell Biochem 119:4 (2018 Apr), 2990–2998.
3. Forbes, J.M., Cooper, M.E., Mechanisms of diabetic complications. Physiol Rev 93 (2013), 137–188.
4. Kerner, W., Brückel, J., Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 122 (2014), 384–386.
5. McClelland, A.D., Kantharidis, P., microRNA in the development of diabetic complications. Clin Sci 126 (2014), 95–110.
6. Chien, H.-Y., Lee, T.-P., Chen, C.-Y., Chiu, Y.-H., Lin, Y.-C., Lee, L.-S., et al. Circulating microRNA as a diagnostic marker in populations with type 2 diabetes mellitus and diabetic complications. J Chin Med Assoc 78 (2015), 204–211.
7. Sohel, M.H., Extracellular/circulating microRNAs: release mechanisms, functions and challenges. Achieve Life Sci 10 (2016), 175–186.
8. Kurtz, C.L., Peck, B.C., Fannin, E.E., Beysen, C., Miao, J., Landstreet, S.R., et al. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 63:9 (2014 Sep), 3141–3148.
9. Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
10. Hall, E., Volkov, P., Dayeh, T., Esguerra, J.L.S., Salö S., Eliasson, L., et al. Sex differences in the genome-wide DNA methylation pattern and impact on gene expression, microRNA levels and insulin secretion in human pancreatic islets. Genome Biol, 15, 2014, 522.
11. Lee, Y., Kim, M., Han, J., Yeom, K.H., Lee, S., Baek, S.H., et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23 (2004), 4051–4060.
12. Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol, 15, 2014, 509.
13. Lam, J.K., Chow, M.Y., Zhang, Y., Leung, S.W., siRNA versus miRNA as therapeutics for gene silencing. Mol Ther–Nucleic Acids, 4, 2015, e252.
14. Lin, S., Gregory, R.I., MicroRNA biogenesis pathways in cancer. Nat Rev Cancer, 15, 2015, 321.
15. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
16. Valinezhad Orang, A.A.-O., Safaralizadeh, R.A.-O., Kazemzadeh-Bavili, M., Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. 2014, 970607.
17. Hammond, S.M., An overview of microRNAs. Adv Drug Deliv Rev 87 (2015), 3–14.
18. Klein, D., Misawa, R., Bravo-Egana, V., Vargas, N., Rosero, S., Piroso, J., et al. MicroRNA expression in alpha and beta cells of human pancreatic islets. PLoS One, 8, 2013, e55064.
19. Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P.E., et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432 (2004), 226–230.
20. Esau, C., Kang, X., Peralta, E., Hanson, E., Marcusson, E.G., Ravichandran, L.V., et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 279 (2004), 52361–52365.
21. Plaisance, V., Abderrahmani, A., Perret-Menoud, V., Jacquemin, P., Lemaigre, F., Regazzi, R., MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 281 (2006), 26932–26942.
22. Herrera, B.M., Lockstone, H.E., Taylor, J.M., Wills, Q.F., Kaisaki, P.J., Barrett, A., et al. MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of type 2 diabetes. BMC Med Genet, 2, 2009, 54.
23. Belgardt, B.-F., Ahmed, K., Spranger, M., Latreille, M., Denzler, R., Kondratiuk, N., et al. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med 21 (2015), 619–627.
24. Lynn, F.C., Skewes-Cox, P., Kosaka, Y., McManus, M.T., Harfe, B.D., German, M.S., MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 56 (2007), 2938–2945.
25. Ruan, Q., Wang, T., Kameswaran, V., Wei, Q., Johnson, D.S., Matschinsky, F., et al. The microRNA-21– PDCD4 axis prevents type 1 diabetes by blocking pancreatic β cell death. Proc Natl Acad Sci 108 (2011), 12030–12035.
26. Li, X., MiR-375, a microRNA related to diabetes. Gene 533 (2014), 1–4.
27. Caporali, A., Meloni, M., Völlenkle, C., Bonci, D., Sala-Newby, G.B., Addis, R., et al. Deregulation of microRNA-503 contributes to diabetes mellitus–induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123:3 (2011 Jan 25), 282–291.
28. Argyropoulos, C., Wang, K., Bernardo, J., Ellis, D., Orchard, T., Galas, D., et al. Urinary MicroRNA profiling predicts the development of microalbuminuria in patients with type 1 diabetes. J Clin Forensic Med 4 (2015), 1498–1517.
29. Kantharidis, P., Wang, B., Carew, R.M., Lan, H.Y., Diabetes complications: the microRNA perspective. Diabetes 60 (2011), 1832–1837.
30. Shantikumar, S., Rovira-Llopis, S., Spinetti, G., Emanueli, C., MicroRNAs in diabetes and its vascular complications. Non-coding RNAs in the vasculature. 2017, Springer, 39–59.
31. He, Y., Ding, Y., Liang, B., Lin, J., Kim, T.K., Yu, H., et al. A systematic study of dysregulated microRNA in type 2 diabetes mellitus. Int J Mol Sci, 18, 2017.
32. Flowers, E., Aouizerat, B.E., Abbasi, F., Lamendola, C., Grove, K.M., Fukuoka, Y., et al. Circulating microRNA-320a and microRNA-486 predict thiazolidinedione response: moving towards precision health for diabetes prevention. Metab Clin Exp 64 (2015), 1051–1059.
33. Flowers, E., Froelicher, E.S., Aouizerat, B.E., MicroRNA regulation of lipid metabolism. Metab Clin Exp 62 (2013), 12–20.
34. De Rosa, S., Arcidiacono, B., Chiefari, E., Brunetti, A., Indolfi, C., Foti, D.P., Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol, 9, 2018, 2.
35. Engelmann, I., Alidjinou, E.K., Bertin, A., Bossu, J., Villenet, C., Figeac, M., et al. Persistent coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic cells. Cell Mol Life Sci, 2017, 1–11.
36. Ashoori, M.R., Rahmati-Yamchi, M., Ostadrahimi, A., Fekri Aval, S., Zarghami, N., MicroRNAs and adipocytokines: promising biomarkers for pharmacological targets in diabetes mellitus and its complications. Biomed Pharmacother 93 (2017), 1326–1336.
37. Zhu, H., Leung, S.W., Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. 2015, Springer.
38. Karolina, D.S., Armugam, A., Tavintharan, S., Wong, M.T., Lim, S.C., Sum, C.F., et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One, 6, 2011, e22839.
39. Al-Muhtaresh, H.A., Al-Kafaji, G., Evaluation of two-diabetes related microRNAs suitability as earlier blood biomarkers for detecting prediabetes and type 2 diabetes mellitus. J Clin Forensic Med, 7, 2018.
40. Tattikota, S.G., Rathjen, T., Hausser, J., Khedkar, A., Kabra, U.D., Pandey, V., et al. MiR-184 regulates pancreatic β-cell function according to glucose metabolism. J Biol Chem 290 (2015), 20284–20294.
41. Coskun, E., Ercin, M., Gezginci-Oktayoglu, S., The role of epigenetic regulation and pluripotency-related microRNas in differentiation of pancreatic stem cells to beta cells. J Cell Biochem 119:1 (2018 Jan), 455–467.
42. Samandari, N., Mirza, A.H., Nielsen, L.B., Kaur, S., Hougaard, P., Fredheim, S., et al. Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus. Diabetologia 60 (2017), 354–363.
43. LaPierre, M.P., Stoffel, M., MicroRNAs as stress regulators in pancreatic beta cells and diabetes. Mol Metab 6 (2017), 1010–1023.
44. Sebastiani, G., Valentini, M., Grieco, G.E., Ventriglia, G., Nigi, L., Mancarella, F., et al. MicroRNA expression profiles of human iPSCs differentiation into insulin-producing cells. Acta Diabetol 54 (2017), 265–281.
45. Bai, C., Gao, Y., Li, X., Wang, K., Xiong, H., Shan, Z., et al. MicroRNAs can effectively induce formation of insulin-producing cells from mesenchymal stem cells. J Tissue Eng Regen Med 11 (2017), 3457–3468.
46. Tsukita, S., Yamada, T., Takahashi, K., Munakata, Y., Hosaka, S., Takahashi, H., et al. MicroRNAs 106b and 222 improve hyperglycemia in a mouse model of insulin-deficient diabetes via pancreatic β-cell proliferation. EBioMedicine 15 (2017), 163–172.
47. Martinez-Sanchez, A., Nguyen-Tu, M.-S., Rutter, G.A., DICER inactivation identifies pancreatic β-cell “disallowed” genes targeted by microRNAs. Mol Endocrinol 29 (2015), 1067–1079.
48. Vienberg, S., Geiger, J., Madsen, S., Dalgaard, L.T., MicroRNAs in metabolism. Acta Physiol 219 (2017), 346–361.
49. Grieco, F.A., Sebastiani, G., Juan-Mateu, J., Villate, O., Marroqui, L., Ladrière, L., et al. MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p regulate the expression of proapoptotic BH3-only proteins DP5 and PUMA in human pancreatic β-cells. Diabetes 66 (2017), 100–112.
50. Sims, E.K., Lakhter, A.J., Anderson-Baucum, E., Kono, T., Tong, X., Evans-Molina, C., MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells. Diabetologia 60 (2017), 1057–1065.
51. Anuradha, R., Saraswati, M., Kumar, K.G., Rani, S.H., Apoptosis of beta cells in diabetes mellitus. DNA Cell Biol 33 (2014), 743–748.
52. Vivacqua, A., De Marco, P., Belfiore, A., Maggiolini, M., Recent advances on the role of microRNAs in both insulin resistance and cancer. Curr Pharm Des 23 (2017), 3658–3666.
53. He, A., Zhu, L., Gupta, N., Chang, Y., Fang, F., Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 21 (2007), 2785–2794.
54. Ling, H.Y., Ou, H.S., Feng, S.D., Zhang, X.Y., Tuo, Q.H., Chen, L.X., et al. CHANGES IN microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin Exp Pharmacol Physiol 36 (2009), e32–e39.
55. Ryu, H.S., Park, S.-Y., Ma, D., Zhang, J., Lee, W., The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS One, 6, 2011, e17343.
56. Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474 (2011), 649–653.
57. Lu, H., Buchan, R.J., Cook, S.A., MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 86 (2010), 410–420.
58. Yang, Y.M., Seo, S.Y., Kim, T.H., Kim, S.G., Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid. Hepatology 56 (2012), 2209–2220.
59. Hung, T.-M., Ho, C.-M., Liu, Y.-C., Lee, J.-L., Liao, Y.-R., Wu, Y.-M., et al. Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma. PLoS One, 9, 2014, e89446.
60. Hubal, M.J., Nadler, E.P., Ferrante, S.C., Barberio, M.D., Suh, J.H., Wang, J., et al. Circulating adipocyte-derived exosomal MicroRNAs associated with decreased insulin resistance after gastric bypass. Obesity 25 (2017), 102–110.
61. Latreille, M., Hausser, J., Stützer, I., Zhang, Q., Hastoy, B., Gargani, S., et al. MicroRNA-7a regulates pancreatic β cell function. J Clin Invest, 124, 2014, 2722.
62. Lovis, P., Gattesco, S., Regazzi, R., Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 389 (2008), 305–312.
63. Sebastiani, G., Po, A., Miele, E., Ventriglia, G., Ceccarelli, E., Bugliani, M., et al. MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol 52 (2015), 523–530.
64. Bagge, A., Clausen, T.R., Larsen, S., Ladefoged, M., Rosenstierne, M.W., Larsen, L., et al. MicroRNA-29a is up-regulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion. Biochem Biophys Res Commun 426 (2012), 266–272.
65. Frost, R.J., Olson, E.N., Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci 108 (2011), 21075–21080.
66. Kalis, M., Bolmeson, C., Esguerra, J.L., Gupta, S., Edlund, A., Tormo-Badia, N., et al. Beta-cell specific deletion of Dicer1 leads to defective insulin secretion and diabetes mellitus. PLoS One, 6, 2011, e29166.
67. Lima, T.I., Araujo, H.N., Menezes, E.S., Sponton, C.H., Araújo, M.B., Bomfim, L.H., et al. Role of microRNAs on the regulation of mitochondrial biogenesis and insulin signaling in skeletal muscle. J Cell Physiol 232 (2017), 958–966.
68. Russell, A.P., Lamon, S., Boon, H., Wada, S., Güller, I., Brown, E.L., et al. Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short-term endurance training. J Physiol 591 (2013), 4637–4653.
69. Horie, T., Ono, K., Nishi, H., Iwanaga, Y., Nagao, K., Kinoshita, M., et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 389 (2009), 315–320.
70. Wu, H., Zhang, T., Pan, F., Steer, C.J., Li, Z., Chen, X., et al. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis. J Hepatol 66 (2017), 816–824.
71. Gu, T.T., Song, L., Chen, T.Y., Wang, X., Zhao, X.J., Ding, X.Q., et al. Fructose downregulates miR-330 to induce renal inflammatory response and insulin signaling impairment: attenuation by morin. Mol Nutr Food Res, 2017, 10.1002/mnfr.201600760.
72. Motohashi, N., Alexander, M.S., Shimizu-Motohashi, Y., Myers, J.A., Kawahara, G., Kunkel, L.M., Regulation of IRS1/Akt insulin signaling by microRNA-128a during myogenesis. J Cell Sci 126 (2013), 2678–2691.
73. Chakraborty, C., Doss, C., Bandyopadhyay, S., Agoramoorthy, G., Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes. Wiley Interdiscip Rev RNA 5 (2014), 697–712.
74. Zhou, J.Y., Xu, B., Li, L.A., New role for an old drug: metformin targets microRNAs in treating diabetes and cancer. Drug Dev Res 76 (2015), 263–269.
75. Zhang, Y., Chen, F., Wang, L., Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p. Am J Transl Res 9 (2017), 5558–5566.
76. Noren Hooten, N., Martin-Montalvo, A., Dluzen, D.F., Zhang, Y., Bernier, M., Zonderman, A.B., et al. Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence. Aging Cell 15 (2016), 572–581.
77. Pulito, C., Donzelli, S., Muti, P., Puzzo, L., Strano, S., Blandino, G., microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med, 2, 2014, 58.
78. Yu, J., Kong, X., Liu, J., Lv, Y., Sheng, Y., Lv, S., et al. Expression profiling of PPARgamma-regulated microRNAs in human subcutaneous and visceral adipogenesis in both genders. Endocrinology 155 (2014), 2155–2165.
79. Ying, W., Tseng, A., Chang, R.C., Morin, A., Brehm, T., Triff, K., et al. MicroRNA-223 is a crucial mediator of PPARgamma-regulated alternative macrophage activation. J Clin Invest 125 (2015), 4149–4159.
80. Hong, S.J., Choi, S.C., Cho, J.Y., Joo, H.J., Park, J.H., Yu, C.W., et al. Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis. Circ J 79 (2015), 880–888.
81. Zhao, N., Yu, H., Yu, H., Sun, M., Zhang, Y., Xu, M., et al. MiRNA-711-SP1-collagen-I pathway is involved in the anti-fibrotic effect of pioglitazone in myocardial infarction. Sci China Life Sci 56 (2013), 431–439.
82. Ye, Y., Hu, Z., Lin, Y., Zhang, C., Perez-Polo, J.R., Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 87 (2010), 535–544.
83. Yamashita, Y., Asakura, M., Mitsugi, R., Fujii, H., Nagai, K., Atsuda, K., et al. MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells. Drug Metab Pharmacokinet 31 (2016), 201–209.
84. Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63 (2014), 2120–2131.
85. Civantos, E., Bosch, E., Ramirez, E., Zhenyukh, O., Egido, J., Lorenzo, O., et al. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway. Diabetes Metab Syndr Obes 10 (2017), 207–222.
86. Guo, J., Fang, W., Sun, L., Lu, Y., Dou, L., Huang, X., et al. Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription of srebp1. Oncotarget 7 (2016), 36207–36219.
87. Song, I., Roels, S., Martens, G.A., Bouwens, L., Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds. PLoS One, 12, 2017, e0186480.
88. Lee, I.S., Park, K.C., Yang, K.J., Choi, H., Jang, Y.S., Lee, J.M., et al. Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice. Obes Res Clin Pract 10 (2016), 315–326.
89. Li, J., Su, L., Gong, Y.Y., Ding, M.L., Hong, S.B., Yu, S., et al. Downregulation of miR-139-5p contributes to the antiapoptotic effect of liraglutide on the diabetic rat pancreas and INS-1 cells by targeting IRS1. PLoS One, 12, 2017, e0173576.
90. Xu, X., Chen, J., Hu, L., Liang, M., Wang, X., Feng, S., et al. Liraglutide regulates the viability of pancreatic alpha-cells and pancreatic beta-cells through cAMP-PKA signal pathway. Life Sci 195 (2018 Feb 15), 87–94.
91. Athyros, V.G., Katsiki, N., Karagiannis, A., Editorial: microRNAs: potential targets for the treatment of cardiovascular disease. Curr Vasc Pharmacol 13 (2015), 366–367.
92. Katsiki, N., Athyros, V.G., Mikhailidis, D.P., Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. Curr Med Res Opin 32 (2016), 1513–1514.
93. Prattichizzo, F., De Nigris, V., Spiga, R., Mancuso, E., La Sala, L., Antonicelli, R., et al. Inflammageing and metaflammation: the yin and yang of type 2 diabetes. Ageing Res Rev 41 (2017), 1–17.
94. Zaiou, M., El Amri, H., Bakillah, A., The clinical potential of adipogenesis and obesity-related microRNAs. Nutr Metab Cardiovasc Dis 28 (2018), 91–111.
95. Peng, Y., Yu, S., Li, H., Xiang, H., Peng, J., Jiang, S., MicroRNAs: emerging roles in adipogenesis and obesity. Cell Signal 26 (2014), 1888–1896.
96. Hang, P., Guo, J., Sun, C., Du, Z., MicroRNAs as candidate drug targets for cardiovascular diseases. Curr Drug Targets 18 (2017), 463–472.
97. Borck, P.C., Batista, T.M., Vettorazzi, J.F., Soares, G.M., Lubaczeuski, C., Guan, D., et al. Nighttime light exposure enhances Rev-erbalpha-targeting microRNAs and contributes to hepatic steatosis. Metab Clin Exp, 2018, 10.1016/j.metabol.2018.05.002.
98. Murri, M., Insenser, M., Fernandez-Duran, E., San-Millan, J.L., Luque-Ramirez, M., Escobar-Morreale, H.F., Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. Metab Clin Exp, 2018, 10.1016/j.metabol.2018.01.011.
99. Huang, Y., Cai, X., Hu, Y., The important role of microRNAs in lipid metabolism. Metab Clin Exp 62 (2013), e1–e2.
100. Wu, H.L., Heneidi, S., Chuang, T.Y., Diamond, M.P., Layman, L.C., Azziz, R., et al. The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome. J Clin Endocrinol Metab 99 (2014), E2754–E2761.
101. DiStefano, J.K., Gerhard, G.S., Circulating microRNAs in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 10 (2016), 161–163.
102. Eisenberg, I., Nahmias, N., Novoselsky Persky, M., Greenfield, C., Goldman-Wohl, D., Hurwitz, A., et al. Elevated circulating micro-ribonucleic acid (miRNA)-200b and miRNA-429 levels in anovulatory women. Fertil Steril 107 (2017), 269–275.
103. Canfran-Duque, A., Lin, C.S., Goedeke, L., Suarez, Y., Fernandez-Hernando, C., Micro-RNAs and high-density lipoprotein metabolism. Arterioscler Thromb Vasc Biol 36 (2016), 1076–1084.
104. Athyros, V.G., Tziomalos, K., Karagiannis, A., Mikhailidis, D.P., Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is coming soon; let us combine them all. Curr Pharm Des 20 (2014), 6350–6357.
105. Athyros, V.G., Alexandrides, T.K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E.S., et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metab Clin Exp 71 (2017), 17–32.
106. Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metab Clin Exp 65 (2016), 1109–1123.
107. Anagnostis, P., Tarlatzis, B.C., Kauffman, R.P., Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metab Clin Exp, 2017, 10.1016/j.metabol.2017.09.016.
108. Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms. Pharmacol Res 130 (2018), 451–465.
109. Asgary, S., Rafieian-Kopaei, M., Shamsi, F., Najafi, S., Sahebkar, A., Biochemical and histopathological study of the anti-hyperglycemic and anti-hyperlipidemic effects of cornelian cherry (Cornus mas L.) in alloxan-induced diabetic rats. J Complement Integr Med 11:2 (2014), 63–69.
110. Yousefi, H., Alihemmati, A., Karimi, P., Alipour, M.R., Habibi, P., Ahmadiasl, N., Effect of genistein on expression of pancreatic SIRT1, inflammatory cytokines and histological changes in ovariectomized diabetic rat. Iran J Basic Med Sci 20:4 (2017), 423–429.
111. Bulboacă A., Bolboacă S.D., Suciu, H.S., Protective effect of curcumin in fructose-induced metabolic syndrome and in streptozotocin-induced diabetes in rats. Iran J Basic Med Sci 19:6 (2016), 585–593.
112. Becker, N., Lockwood, C.M., Pre-analytical variables in miRNA analysis. Clin Biochem 46 (2013), 861–868.
113. Kalogianni, D.P., Kalligosfyri, P.M., Kyriakou, I.K., Christopoulos, T.K., Advances in microRNA analysis. Anal Bioanal Chem 410 (2018), 695–713.
114. Mao, Y., Mohan, R., Zhang, S., Tang, X., MicroRNAs as pharmacological targets in diabetes. Pharmacol Res 75 (2013), 37–47.
115. Ishida, M., Selaru, F.M., miRNA-based therapeutic strategies. Curr Anesthesiol Rep 1 (2013), 63–70.